论文部分内容阅读
目的观察EP与TP方案同步化放疗治疗Ⅲ期非小细胞肺癌的疗效。方法86例Ⅲ期非小细胞肺癌患者随机分为TP组42例和EP组44例,EP组采用EP方案化疗4个周期,TP组采用TP方案化疗4个周期,并于第1周期化疗第1天开始放疗。两组放射治疗均采用6MVX直线加速器常规分割治疗,放射治疗总量DT60～70Gy,6～7周完成。结果EP组CR8例,PR30例,有效率(CR+PR)86.4%;TP组CR8例,PR29例,有效率(CR+PR)88.1%,两组有效率差异无统计学意义(P>0.05)。EP组1、2、3年生存率分别为65.9%、45.5%、29.5%;TP组和EP组中位生存期分别为19.2个月和l8.5个月。2组间中位生存期及1、2、3年生存率差异无统计学意义(P>0.05)。两组的恶心、呕吐、骨髓抑制、放射性食管炎和放射性肺炎发生差异无统计学意义(P>0.05)。结论EP与TP方案同步化放疗均能对Ⅲ期NSCLC起到很好的疗效,TP组在近期有效率、中位生存期及2、3年生存期上均较EP组高;而EP组的不良反应发生率较低,患者的生活质量和治疗依从性相对较好,但二组之间的差异无统计学意义
Objective To observe the efficacy of EP and TP regimen synchronized radiotherapy for stage Ⅲ non-small cell lung cancer. Methods Totally 86 patients with stage Ⅲ NSCLC were randomly divided into TP group (n = 42) and EP group (n = 44). Patients in EP group were treated with EP regimen for 4 cycles and TP group were treated with TP regimen (4 cycles). In the first cycle of chemotherapy 1 day to start radiotherapy. Radiation therapy were used 6MVX linear accelerator routine division treatment, the total radiation therapy DT60 ~ 70Gy, 6 to 7 weeks to complete. Results There were 8 CR cases and 30 PR cases in the EP group, with an effective rate of (CR + PR) 86.4%. There were 8 CR cases and 29 PR cases in the TP group, the CR rate was 88.1%. There was no significant difference between the two groups ). The 1, 2, 3-year survival rates of EP group were 65.9%, 45.5% and 29.5%, respectively. The median survival time of TP group and EP group were 19.2 months and 8.5 months respectively. There was no significant difference in the median survival time and the 1, 2, 3 year survival rates between the two groups (P> 0.05). Nausea, vomiting, myelosuppression, radiation esophagitis and radiation pneumonitis had no significant difference between the two groups (P> 0.05). Conclusions Both EP and TP regimens are effective in the treatment of stage Ⅲ NSCLC. The effective rate, median survival time and 2-3 year survival rate of TP group are higher than that of EP group. In EP group The incidence of adverse reactions was lower, and the quality of life and treatment compliance were better in patients, but there was no significant difference between the two groups